Single and Multiple Ascending Doses and Food Effect Study of TRD205 in Healthy Volunteers

NCT ID: NCT07123428

Last Updated: 2025-08-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 151 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-26
• Study Completion Date: 2025-02-27

Brief Summary

This is a Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of TRD205 after single and multiple doses and to evaluate the effect of food on TRD205 in healthy adult subjects.

Detailed Description

This study consists of three parts:

• Single ascending dose study
• Multiple ascending dose study
• Food effect study

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

TRD205: Single ascending dose (SAD) study

TRD205: oral, single ascending doses up to 7 doses levels.

Group Type: EXPERIMENTAL

TRD205

Intervention Type: DRUG

TRD205 tablet

Placebo: Single ascending dose (SAD) study

Placebo: oral, TRD205 placebo in single ascending doses study.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

TRD205 placebo tablet

TRD205: Food effect study

TRD205: oral, just 1 dose under fasted or fed condition for each period.

Group Type: EXPERIMENTAL

TRD205

Intervention Type: DRUG

TRD205 tablet

Placebo: Food effect study

Placebo: oral, under fasted or fed condition for each period.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

TRD205 placebo tablet

Multiple ascending dose (MAD) study

TRD205: oral, multiple ascending doses up to 4 doses levels. Doses and dosing frequency will be decided based on SAD results.

Group Type: EXPERIMENTAL

TRD205

Intervention Type: DRUG

TRD205 tablet

Interventions

TRD205

TRD205 tablet

Intervention Type: DRUG

Placebo

TRD205 placebo tablet

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects who can understand the requirements and potential side effects of the study and voluntarily sign the informed consent form.

• Able to complete the study per protocol and communicate with the investigators.
• Subjects (and their sexual partners) should voluntarily practice effective contraception per protocol.
• Healthy subjects aged 18-55 years.
• Body weight should be ≥ 50 kg for male subjects and ≥ 45 kg for female subjects with a body mass index of 18-28 kg/m2.
• Physical examination and vital sign: normal or are considered by the investigator to be of no clinical significance.
• No vaccination within 30 days prior to screening.

Exclusion Criteria

• Smoking 5 or more cigarettes per day within 3 months before screening.
• Subjects with an allergic constitution, such as a history of allergy to two or more drugs or food.
• Subjects who have a history of drug abuse and or alcoholism.
• Subjects who have had blood donation and/or blood loss ≥ 450 mL wihin 3 months before screening.
• Subjects who have consumed medications known to alter hepatic drug metabolism enzyme activity within 28 days before screening.
• Subjects who have taken any other prescription medication, OTC products, vitamins or herbal products within 14 days before screening, except for those exempted by the investigator on a case-by-case basis.
• Subjects who have eaten special food, such as dragon fruit, mango, pomelo, grapefruit, cranberry and their juice, or had vigorous exercise, or had other factors that may influence the ADME process of drug.
• Subjects who have concomitant drugs that induce or inhibit CYP3A4, P-gp, Bcrp.
• Subjects who have consumed investigational products or participated in drug clinical trials within 3 months before taking IP.
• Subjects who have dysphagia or other gastrointestinal diseases that can influence drug adsorption.
• Subjects who can not tolerate the standard meal (just for those who participate the food effect study).
• 12-lead ECG: abnormal results and considered by the investigator to be of clinical significance.
• Pregnant or lactating women.
• Laboratory tests: abnormal results and considered by the investigator to be of clinical significance. Or subjects with the diseases of gastrointestinal tract, kidney, liver, nervous system, blood system, endocrinal system, tumor, lung, immunity, mental system, cardiovascular system, cerebral vascular system within 12 months before screening.
• Positive serological tests for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and treponema pallidum (TP) at screening.
• Subjects who have had acute disease or concomitant drugs from screening to taking IP.
• Subjects who have consumed chocolate, Caffeine-containing products or xanthine containing food (such as tea, coffee, colar) within 48 hours beforing taking IP.
• Subjects who have consumed alcohol-containing products within 48 hours beforing taking IP.
• Subjects who have a positive urine drug screening test result.
• Subject who have received surgery within 4 weeks before taking IP.
• Subject who are not ready to abstain from participation in any other clinical study for the duration of this study and for 30 days or more (as required by the investigator) after completion of the study.
• Mental or physical disability.
• Subject cannot tolerate venipuncture blood collection or has a history of sickness at the sight of blood and/or needle.
• Any reason that, in the opinion of the Investigator, may prevent the subject from participating in the study.
• Subjects who have the risk factors of torsade de pointes, or a family history of a first-degree relative with short QT syndrome, long QT syndrome, unexplained sudden death in youth, drowning, or sudden infant death syndrome.
• Subjects with abnormal and clinically significant hyperkalemia, hypokalemia, hypermagnesemia, hypomagnesemia, hypercalcemia or hypocalcemia as judged by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Beijing Tide Pharmaceutical Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The first hospital of Jilin University

Changchun, Jilin, China

Countries

China

Other Identifiers

TRD205-Ⅰ-01

Identifier Type: -

Identifier Source: org_study_id